Highest-materiality recent filing
Cencora names Samantha Hammock as CHRO replacing retiring Silvana Battaglia
Silvana Battaglia retires as EVP & CHRO effective July 12, 2026 after 7 years.
Appoints Eva Boratto as EVP and CFO effective June 29, 2026; succeeds James Cleary retiring.
Cencora Q2 revenue $78.4B (+3.8%); adj. EPS $4.75 (+7.5%); FY2026 guidance raised
GAAP diluted EPS $8.40 vs $3.68; adjusted diluted EPS $4.75 vs $4.42 (+7.5%).
Cencora to buy EyeSouth retina business for $1.1B; expects slight EPS accretion
Acquires EyeSouth Partners' retina business for $1.1B; physicians to join Retina Consultants of America.
Cencora CFO James F. Cleary to retire June 30, 2026; FY2026 guidance reaffirmed
James F. Cleary, EVP and CFO, will retire effective June 30, 2026; advisory role through end of 2026.
Cencora shareholders elect all 11 directors, approve say-on-pay, ratify EY as auditor
All 11 director nominees elected; for votes ranged from ~163.3M to ~168.5M, with broker non-votes of 9.7M.
MWI valued at $3.5B enterprise value; Cencora gets $1.25B cash, $800M preferred units, $1.45B common units.
Cencora closes $3.0B senior notes offering, proceeds to repay OneOncology acquisition debt
$500M each of 3.950% notes due 2029, 4.250% notes due 2030, 4.600% notes due 2033, 5.650% notes due 2056; $1.0B of 4.900% notes due 2036.
$3.0B aggregate of senior notes in five tranches: 2029 (3.950%), 2030 (4.250%), 2033 (4.600%), 2036 (4.900%), 2056 (5.650%).
New segments: U.S. Healthcare Solutions, International Healthcare Solutions, and Other.
Cencora Q1 EPS $2.87 GAAP, $4.08 adjusted; acquires OneOncology for $4.6B
Revenue $85.9B, +5.5% YoY; GAAP diluted EPS $2.87 vs $2.50 prior year; adjusted diluted EPS $4.08 vs $3.73, +9.4%.
Cencora elects Ellen Cooper, CEO of Lincoln Financial, to its board
Ellen Cooper appointed independent director effective Jan. 20, 2026; board expands from 10 to 11 members.
Cencora secures $5.5B in financing for OneOncology acquisition; $4.5B bridge replaced
Revolving credit facility increased by $1.0B to $5.5B via amendment on Jan 12, 2026.
Cencora acquires OneOncology majority stake for $3.6B, retires $1.3B debt; total cash ~$5.0B
Enterprise value $7.4B; Cencora paying $3.6B for majority equity and retiring $1.3B OneOncology debt.
Cencora Q4 adj EPS $3.84 (+15%); revenue $83.7B; raises dividend 9%; new segment structure
Q4 GAAP diluted EPS $(1.75) (prior yr $0.02); adjusted EPS $3.84 (+15% YoY); revenue $83.7B (+5.9%).
Cencora amends term loan maturity to Oct 2027; money market facility limit raised to $750M
Term Loan maturity shortened from Jan 2028 to Oct 1, 2027; interest margin unchanged at 62.5-125 bps over Term SOFR.
Cencora reaches $111.3M settlement of derivative suit over opioid oversight
Insurance carriers to pay Cencora $111.3M (less attorney fees) to settle derivative claims over controlled substance diversion controls.
Cencora appoints D. Mark Durcan as Chairman effective Oct 1, 2025; Steven H. Collis retires
D. Mark Durcan named Chairman of the Board, effective October 1, 2025, succeeding Steven H. Collis.
Cencora Q3 FY2025 revenue $80.7B (+8.7% YoY); adj. EPS $4.00, guidance raised to $15.85-$16.00
Revenue $80.7B (+8.7% YoY); GAAP diluted EPS $3.52 vs $2.42; adj. EPS $4.00, up 19.8%.
Cencora increases receivables facility to $1.5B and doubles accordion to $500M
Receivables securitization facility raised to $1.5B from $1.45B; accordion feature increased to $500M from $250M.
Cencora upsizes revolver to $4.5B, extends maturity to 2030; terminates $1.0B 364-day facility
Amended revolving credit facility increased to $4.5 billion aggregate commitments; maturity extended to June 4, 2030.
Cencora adds Lori Ryerkerk to board; director Barra resigns amid WBA stake drop
Lori J. Ryerkerk, former Celanese CEO, elected independent director effective June 1, 2025.
Cencora issues €1B in senior notes across 2028 and 2032 maturities
Issued €500M of 2.875% Senior Notes due May 22, 2028.
Cencora prices €1B dual-tranche senior notes (2.875% due 2028, 3.625% due 2032)
€500M 2.875% senior notes due 2028 and €500M 3.625% senior notes due 2032 issued.
Cencora Q2 FY2025 revenue $75.5B (+10.3% YoY); adj. EPS $4.42 (+16.3%); raises FY guidance
Revenue $75.5B, +10.3% YoY; GAAP diluted EPS $3.68 vs $2.09 prior year.
Cencora raises FY2025 adjusted EPS guidance range by $0.05 to $15.30-$15.60
Guidance increase driven by continued momentum in U.S. Healthcare Solutions segment during Q2 2025.
Cencora shareholders elect 11 directors, approve executive compensation, ratify EY
All 11 director nominees elected; Lon Greenberg received highest opposition with 15.7M against votes.
Cencora repurchases $50M of common stock from Walgreens Boots Alliance
Repurchased 204,491 shares at price equal to Walgreens' Rule 144 sale, aggregate $50M.
Cencora Q1 revenue $81.5B +12.8% YoY; adjusted EPS $3.73, raises FY2025 guidance
Revenue $81.5B (+12.8% YoY); GAAP diluted EPS $2.50 (down from $2.98); adjusted diluted EPS $3.73 (+13.7%).
Two Cencora directors to retire at March 6 annual meeting; board size to shrink to 11
Richard W. Gochnauer (director since 2008) and Kathleen W. Hyle (since 2010) will retire at the Annual Meeting on March 6, 2025.
Cencora acquires ~85% interest in Retina Consultants of America for $4.4B cash outlay, with post-closing adjustment.
Cencora closes $1.8B senior notes offering to fund Retina Consultants of America acquisition
Issued $500M 4.625% notes due 2027, $600M 4.850% notes due 2029, $700M 5.150% notes due 2035.
Cencora prices $1.8B debt offering in three tranches to fund Retina Consultants acquisition
$500M 4.625% senior notes due 2027, $600M 4.850% notes due 2029, $700M 5.150% notes due 2035 priced.
Cencora enters $1.5B term loan and $1.0B revolver to fund Retina Consultants of America acquisition
$1.5B senior unsecured term loan entered Nov 26, 2024; matures 3 years from draw.
Cencora to acquire Retina Consultants of America for $4.6B, ~85% ownership, accretive $0.35
Enterprise value of $4.6B cash; expected cash outlay ~$4.3B after physician/management rollover and fees.
Cencora Q4 adjusted EPS $3.34, revenue $79.1B (+14.7% YoY); dividend up 8%
Q4 GAAP EPS $0.02 vs $1.72 prior year; adjusted EPS $3.34 (+16.8% YoY) on revenue $79.1B (+14.7% YoY).
Cencora amends revolver and securitization facilities, extends maturities to 2029/2027
Revolving credit facility maturity extended to October 9, 2029; facility fees reduced.
Adjusted diluted EPS for FY2024 raised to $13.60-$13.70 from prior $13.55-$13.65.
Cencora entered into indemnification agreements with board members and executive officers, effective August 13, 2024.
Cencora elects Frank Clyburn to its board of directors, effective Oct 1, 2024
Frank Clyburn appointed as independent director, effective October 1, 2024.
Cencora repurchases $250M shares from Walgreens; stake reduced to 10.2%
Repurchased 1,039,242 shares from Walgreens Boots Alliance Holdings for ~$250M at market price.
Cencora confirms PII/PHI exfiltration in Feb 2024 cyber incident; notifications ongoing
Exfiltrated data includes personally identifiable and protected health information, most from patient support subsidiary.
Revenue $74.2B (+10.9% YoY); GAAP diluted EPS $2.42 vs $2.35; adjusted diluted EPS $3.34 vs $2.92.
Repurchased 1,859,390 shares at $215.1244/share from Walgreens Boots Alliance Holdings for ~$400M.
Cencora EVP & Chief Communications/Admin Officer Gina Clark to retire Sept 30, 2024
Gina K. Clark, EVP & Chief Communications/Administrative Officer, intends to retire effective September 30, 2024.
Cencora Q2 revenue $68.4B, up 7.8% YoY; adj diluted EPS $3.80, up 8.6%; FY2024 guidance raised
Revenue $68.4B for quarter ended March 31, 2024, +7.8% YoY.
Cencora extends securitization facility to Oct 2026, adds U.S. Bank and Truist as purchasers
Amended receivables purchase agreement to extend facility termination date from Oct 2025 to Oct 21, 2026.
Cencora discloses CEO succession compensation: Mauch $1.35M salary, Collis $1M as Executive Chairman
Robert P. Mauch appointed CEO effective Oct 1, 2024; base salary $1,350,000; joins Board.
Cencora shareholders approve officer exculpation, all 11 directors elected at 2024 annual meeting
Item 4 (officer exculpation amendment) approved: 156M for, 19.4M against, 9M broker non-votes.
Cencora CEO Collis to retire Oct 1, COO Mauch to become President and CEO
Steven H. Collis will retire as CEO on Oct 1, 2024, becoming Executive Chairman for one year.
Ms. Battaglia will be succeeded by Samantha L. Hammock, who will join the Company as Executive Vice President and Chief Human Resources Officer effective July 13, 2026.
On June 15, 2026, Cencora, Inc. (the “Company”) announced that Silvana Battaglia will retire as Executive Vice President and Chief Human Resources Officer of the Company effective July 12, 2026.
On May 27, 2026, Cencora, Inc. (the “Company”) announced that Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company (the “Appointment”), effective June 29, 2026 (the “Effective Date”).
Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously disclosed.
the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”) appointed Lori J. Ryerkerk to serve on the Board (the “Appointment”), with such Appointment to be effective as of June 1, 2025
Ornella Barra informed the Company of her intent to resign from the Board effective immediately
On January 22, 2025, two members of the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”), Richard W. Gochnauer and Kathleen W. Hyle, each informed the Company of their intent to retire as directors at the upcoming Annual Meeting of Stockholders to be held on March 6, 2025 (the “Annual Meeting”).
On January 22, 2025, two members of the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”), Richard W. Gochnauer and Kathleen W. Hyle, each informed the Company of their intent to retire as directors at the upcoming Annual Meeting of Stockholders to be held on March 6, 2025 (the “Annual Meeting”).
On August 13, 2024, the Board of Directors (the "Board") of Cencora, Inc. (the "Company") appointed Frank Clyburn to serve on the Board (the "Appointment"), with such Appointment to be effective as of October 1, 2024 (the "Effective Date").
On April 30, 2024, Gina K. Clark, Executive Vice President and Chief Communications & Administrative Officer of Cencora, Inc. (the “Company”), informed the Company that she intends to retire from her position, effective September 30, 2024.
On March 12, 2024, the Company and Mr. Mauch entered into an amended and restated employment agreement (the “Mauch Employment Agreement”), effective as of the Effective Date.
For a period of one year from the Effective Date, Mr. Collis will serve as Executive Chairman of the Board (the “Executive Chairman Period”).
Max materiality 0.90 · Median 0.60 · Most common event debt